NCT06188741 2026-03-12
NF114
University of Alabama at Birmingham
Phase 2 Recruiting
Clinical Trials
23 trialsNCT02407405 2026-03-05
MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT06541847 2025-11-21
INSPIRE-NF1
Healx Limited
Phase 2 Recruiting
NCT03962543 2025-08-07
ReNeu
SpringWorks Therapeutics, Inc.
Phase 2 Active not recruiting
NCT03231306 2025-05-02
NF108-BINI
University of Alabama at Birmingham
Phase 2 Completed
NCT06763315 2025-01-08
LS-NF1PNs
West China Hospital
Phase 2 Not yet recruiting
NCT03741101 2024-04-11
plexifpc
Region Skane
Phase 2 Active not recruiting
NCT03363217 2023-11-27
Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.
St. Justine's Hospital
Phase 2 Active not recruiting
NCT05825365 2023-08-14
PROTECT
AstraZeneca
Phase 2 Withdrawn
NCT05331105 2023-05-31
HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Shanghai Kechow Pharma, Inc.
Phase 2 Recruiting
NCT02101736 2023-05-24
NF105-CABO
University of Alabama at Birmingham
Phase 2 Completed
NCT03688568 2021-02-12
Study of Imatinib in Children With Neurofibromatosis and Airway Tumors
Indiana University
Phase 2 Withdrawn
NCT02177825 2019-04-08
Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
St. Justine's Hospital
Phase 2 Terminated
NCT03109301 2019-04-05
Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT00030264 2018-08-08
Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
Children's Hospital of Philadelphia
Phase 2 Completed
NCT00076102 2018-04-23
Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00021541 2018-04-17
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01402817 2018-03-14
Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
Indiana University
Phase 2 Terminated
NCT00396019 2017-11-06
Study of PEG-Intron for Plexiform Neurofibromas
University of Pittsburgh
Phase 2 Completed
NCT00326872 2017-08-18
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01365468 2016-05-12
Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)
Novartis
Phase 2 Terminated
NCT01412892 2014-11-14
NFitor
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT00754780 2012-03-19
Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1
Mayo Clinic
Phase 2 Completed